LANCL1-AS1: A Potential Drug Target and Biomarker (G102724820)

Target Name: LANCL1-AS1

NCBI ID: G102724820

LANCL1-AS1

Other Name(s): LANCL1 antisense RNA 1, transcript variant 1 | LANCL1 antisense RNA 1 | LANCLOT | LANCL1-AS1 variant 1

LANCL1-AS1: A Potential Drug Target and Biomarker

LANCL1-AS1, also known as LANCL1 antigen 1, is a protein that is expressed in various tissues and organs, including the brain, spleen, heart, and lungs. It is a member of the LANCL1 family, which is known for its role in cell signaling and development. The LANCL1-AS1 gene has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LANCL1-AS1 protein is known to play a role in the development and progression of various diseases, including cancer. It has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis, which are processes that are critical for the development and progression of cancer. In addition, LANCL1-AS1 has been shown to be involved in the regulation of immune cell function, which is important for the immune response to cancer and other diseases.

As a potential drug target, LANCL1-AS1 is of interest for several reasons. Firstly, it is a protein that is expressed in various tissues and organs, which makes it an attractive target for drugs that can modulate its expression or activity. Secondly, its involvement in cell signaling and development makes it an attractive target for drugs that can modulate its function and contribute to the development and progression of diseases. Finally, its involvement in the regulation of immune cell function makes it an attractive target for drugs that can modulate its function and contribute to the immune response to cancer and other diseases.

In addition to its potential as a drug target, LANCL1-AS1 is also a potential biomarker for several diseases. Its involvement in the regulation of cell signaling and development makes it an attractive target for biomarkers that can be used to diagnose or predict the progression of diseases. For example, LANCL1-AS1 has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. By targeting LANCL1-AS1 with drugs, researchers may be able to develop new diagnostics or treatments for these diseases.

LANCL1-AS1 is a protein that has the potential to be a drug target and biomarker for several diseases. Its involvement in cell signaling and development makes it an attractive target for drugs that can modulate its function. In addition, its involvement in the regulation of immune cell function makes it an attractive target for drugs that can modulate its function and contribute to the immune response to cancer and other diseases. Further research is needed to fully understand the role of LANCL1-AS1 in disease and to develop new treatments based on its potential as a drug target and biomarker.

Protein Name: LANCL1 Antisense RNA 1

The "LANCL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LANCL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets